Pfizer Quietly Advances New Obesity Shot With Fresh Phase 1 Study Update

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

Pfizer Inc. (PFE) is running a Phase 1 study called “A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, PARALLEL GROUP STUDY TO ASSESS RELATIVE BIOAVAILABILITY OF PF-08653944 WHEN ADMINISTERED ACROSS DIFFERENT INJECTION SITES IN ADULTS WITH OVERWEIGHT OR OBESITY.” The goal is to see how a new weight management shot moves into the blood and how safe it looks in adults with overweight or obesity.

The treatment is PF-08653944, also known as MET097, given as a one-time shot under the skin. The medicine is tested at different body sites to see which injection area gives the best and most reliable drug levels.

The study is interventional, meaning participants get an active treatment under controlled conditions. People are randomly assigned to different injection site groups, there is no placebo group, and neither doctors nor patients are blinded, because the main aim is to understand drug behavior rather than compare against standard care.

The trial uses a parallel group model, so each person receives the shot in only one area such as abdomen, thigh, or upper arm. The primary focus is basic science, testing how the drug is absorbed and checking safety signals, rather than measuring direct weight loss outcomes at this early stage.

The study was first submitted on February 3, 2026, marking the formal start of the trial process. It was last updated on February 25, 2026, signaling that the protocol or operational details have been refreshed and the trial is actively managed.

The recruiting status shows enrollment is ongoing, with multiple clinic visits planned for blood tests and vital signs over time. Primary and final completion dates are not posted yet, which is normal for an early-stage program still ramping up.

For investors, this update adds another early asset to Pfizer’s pipeline in the high-growth obesity and metabolic space. While Phase 1 safety and drug level data rarely move PFE stock on their own, they help support a longer-term narrative that Pfizer is building optionality beyond its core vaccines and oncology businesses.

The focus on different injection sites hints at plans for a patient-friendly dosing profile, which is important in a market crowded by GLP-1 players like Eli Lilly and Novo Nordisk. If PF-08653944 later shows solid efficacy and ease of use, it could support sentiment that Pfizer can win share in obesity over the next decade.

In the near term, the trial is unlikely to change earnings expectations but it signals steady progress in a strategic therapeutic area. The study remains ongoing and updated details are available on the ClinicalTrials.gov portal under the identifier NCT07400679.

To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.